Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia.

Pridgen WL, Duffy C, Gendreau JF, Gendreau RM.

J Pain Res. 2017 Feb 22;10:451-460. doi: 10.2147/JPR.S127288. eCollection 2017.

2.

Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables.

Abtroun L, Bunouf P, Gendreau RM, Vitton O.

Clin J Pain. 2016 May;32(5):435-40. doi: 10.1097/AJP.0000000000000284.

3.

Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin.

Mease PJ, Farmer MV, Palmer RH, Gendreau RM, Trugman JM, Wang Y.

Ther Adv Musculoskelet Dis. 2013 Jun;5(3):113-26. doi: 10.1177/1759720X13483894.

4.

Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.

Arnold LM, Palmer RH, Gendreau RM, Chen W.

Psychosomatics. 2012 Jul-Aug;53(4):371-9. doi: 10.1016/j.psym.2012.02.005. Epub 2012 Jun 6.

PMID:
22677218
5.

Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia.

Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W.

Curr Med Res Opin. 2012 May;28(5):815-21. doi: 10.1185/03007995.2012.677418. Epub 2012 Apr 10.

PMID:
22429066
6.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update.

Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM; OMERACT Fibromyalgia Working Group.

J Rheumatol. 2011 Jul;38(7):1487-95. doi: 10.3899/jrheum.110277.

7.

A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.

Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ.

Pain Pract. 2011 Mar-Apr;11(2):120-31. doi: 10.1111/j.1533-2500.2010.00403.x.

PMID:
20642487
8.

Role and rationale for the use of milnacipran in the management of fibromyalgia.

Kranzler JD, Gendreau RM.

Neuropsychiatr Dis Treat. 2010 May 25;6:197-208.

9.

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y.

Arthritis Rheum. 2010 Sep;62(9):2745-56. doi: 10.1002/art.27559.

10.

Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran.

Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA.

Pain. 2010 May;149(2):373-8. doi: 10.1016/j.pain.2010.02.043. Epub 2010 Mar 23.

PMID:
20332060
11.

Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.

Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM.

Pain Med. 2010 Feb;11(2):180-94. doi: 10.1111/j.1526-4637.2009.00755.x. Epub 2009 Dec 9.

12.

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH.

J Rheumatol. 2009 Feb;36(2):398-409. doi: 10.3899/jrheum.080734. Erratum in: J Rheumatol. 2009 Mar;36(3):661.

PMID:
19132781
13.

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.

Clin Ther. 2008 Nov;30(11):1988-2004. doi: 10.1016/j.clinthera.2008.11.009. Erratum in: Clin Ther. 2009 Feb;31(2):446. Clin Ther. 2009 Jul;31(7):1617.

PMID:
19108787
14.

Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea.

Marshall NS, Yee BJ, Desai AV, Buchanan PR, Wong KK, Crompton R, Melehan KL, Zack N, Rao SG, Gendreau RM, Kranzler J, Grunstein RR.

Sleep. 2008 Jun;31(6):824-31.

15.

Fibromyalgia syndrome.

Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, Simon LS, Strand CV, Bramson C, Martin S, Wright TM, Littman B, Wernicke JF, Gendreau RM, Crofford LJ.

J Rheumatol. 2005 Nov;32(11):2270-7.

PMID:
16265715
16.

Characterization and consequences of pain variability in individuals with fibromyalgia.

Harris RE, Williams DA, McLean SA, Sen A, Hufford M, Gendreau RM, Gracely RH, Clauw DJ.

Arthritis Rheum. 2005 Nov;52(11):3670-4.

17.

Efficacy of milnacipran in patients with fibromyalgia.

Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ.

J Rheumatol. 2005 Oct;32(10):1975-85.

PMID:
16206355
18.

Self-reported symptoms before and after September 11 in patients with fibromyalgia.

Williams DA, Brown SC, Clauw DJ, Gendreau RM.

JAMA. 2003 Apr 2;289(13):1637-8. No abstract available.

PMID:
12672730
19.

A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis.

Gendreau RM; Prosorba Clinical Trial Group.

Ther Apher. 2001 Apr;5(2):79-83.

PMID:
11354303
20.

Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators.

Furst D, Felson D, Thoren G, Gendreau RM.

Ther Apher. 2000 Oct;4(5):363-73. Erratum in: Ther Apher 2002 Feb;6(1):99.

PMID:
11111818
21.

The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial.

Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Gendreau RM, Harris ER, Matteson EL, Roth SH, Schumacher HR, Weisman MH, Furst DE.

Arthritis Rheum. 1999 Oct;42(10):2153-9.

22.

A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.

Caldwell J, Gendreau RM, Furst D, Wiesenhutter C, Quagliata F, Spindler J, Bertram J.

J Rheumatol. 1999 Aug;26(8):1657-62. Erratum in: J Rheumatol 1999 Dec;26(12):2718.

PMID:
10451058
23.

IR spectral changes of bovine serum albumin upon surface adsorption.

Lenk TJ, Ratner BD, Gendreau RM, Chittur KK.

J Biomed Mater Res. 1989 Jun;23(6):549-69.

PMID:
2738075
24.

Cluster analysis of protein fourier transform infrared spectra.

Lipkus AH, Lenk TJ, Chittur KK, Gendreau RM.

Biopolymers. 1988 Nov;27(11):1831-9. No abstract available.

PMID:
3233334
25.

Quantitative surface studies of protein adsorption by infrared spectroscopy. II. Quantification of adsorbed and bulk proteins.

Fink DJ, Hutson TB, Chittur KK, Gendreau RM.

Anal Biochem. 1987 Aug 15;165(1):147-54.

PMID:
3688429
26.
27.

Effects of flow rate and solution concentration on in situ protein adsorption behavior.

Jakobsen RJ, Brown LL, Winters S, Gendreau RM.

J Biomed Mater Res. 1983 Jan;17(1):199-201. No abstract available.

PMID:
6826575
28.

Spectroscopic probes of blood-surface interaction.

Leininger RI, Fink DJ, Gendreau RM, Hutson TM, Jakobsen RJ.

Trans Am Soc Artif Intern Organs. 1983;29:152-7. No abstract available.

PMID:
6673225
29.

Antepartum prediction of the postmature infant.

Rayburn WF, Motley ME, Stempel LE, Gendreau RM.

Obstet Gynecol. 1982 Aug;60(2):148-53.

PMID:
7155473
30.

Fourier transform infrared spectroscopy for inorganic compound speciation.

Gendreau RM, Jakobsen RJ, Henry WM, Knapp KT.

Environ Sci Technol. 1980 Aug 1;14(8):990-5. doi: 10.1021/es60168a008. No abstract available.

PMID:
22296548
31.
32.

Supplemental Content

Loading ...
Support Center